文献速递膀胱癌与上尿路尿路上皮癌

尿液DNA甲基化作为膀胱癌复发标志物的2中心前瞻性研究

Evaluation of Urinary DNA Methylation as a Marker for Recurrent Bladder Cancer: A 2-Center Prospective Study.
PubMed 文献 · Urology · 2017-11-28

该2中心前瞻性研究纳入132例NMIBC患者,前瞻性收集207份自排尿样本,用亚硫酸氢盐焦磷酸测序分析miRNA基因甲基化。结果显示M-score检测当前复发的敏感性为61.5%、特异性为74.0%,AUC为0.71;高M-score(≥3)与更差的無复发生存相关(P<.01),且是多变量分析中当前复发(P=.028)和晚期复发(P=.026)的独立相关因素。

要点

  • M-score检测当前膀胱内复发的敏感性61.5%、特异性74.0%,AUC为0.71。
  • 高M-score(≥3)患者无复发生存更差(P<.01)。
  • 高M-score与当前复发(P=.028)和晚期复发(P=.026)独立相关。

核心结论

  • 尿液miRNA基因甲基化可能是检测和预测膀胱癌复发的有用标志物。

研究设计与样本

  • 2中心前瞻性研究,从132例接受经尿道膀胱肿瘤电切术的NMIBC患者前瞻性收集207份自排尿样本,用亚硫酸氢盐焦磷酸测序分析miR-9-3、miR-124-2、miR-124-3和miR-137的甲基化。

主要发现

  • 26份尿液标本在检测到膀胱内复发当天收集,14份来自后续随访期间(0-632天,平均342.2天)发现复发的患者。
  • M-score检测当前复发的敏感性为61.5%,特异性为74.0%,ROC曲线下面积为0.71。
  • 高M-score(≥3)患者无复发生存更差(P<.01)。
  • 多变量分析显示高M-score与当前复发独立相关(P=.028),与晚期复发独立相关(P=.026)。
  • 尿液DNA甲基化水平升高与复发和根治性膀胱切除术强烈相关。

临床怎么用

  • 尿液miRNA基因甲基化检测可能有助于发现和预测NMIBC膀胱内复发。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To clarify the clinical utility of urinary DNA methylation for detection of intravesical recurrence of non-muscle invasive BCa (NMIBC), we performed a 2-center prospective study. PATIENTS AND METHODS: A series of 207 self-voided urine samples were prospectively collected from 132 patients with NMIBC who had undergone transurethral resection of BCa. Methylation of miRNA genes (miR-9-3, miR-124-2, miR-124-3, and miR-137) was analyzed using bisulfite pyrosequencing. The primary end point was detection of intravesical recurrence; the secondary end point was prediction of late recurrence. The number of methylated genes (M-score) or quantitative level of methylation were compared with outcomes. RESULTS: Twenty-six urine specimens were collected on the same day intravesical recurrence was detected, and 14 were collected from patients whose recurrences were found during the subsequent follow-up period (0-632 days, mean, 342.2 days). For detection of current recurrence, M-scores achieved 61.5% sensitivity and 74.0% specificity, and the area under the ROC curve was 0.71. Regarding prediction of late recurrence, patients with a high M-score (≥3) showed worse recurrence-free survival (P <.01). Multivariate analysis revealed that high M-scores were independently associated with current (P = .028) and late recurrence (P = .026). Elevated levels of urinary DNA methylation were also strongly associated with recurrence and radical cystectomy. CONCLUSION: Our data suggest that urinary methylation of miRNA genes may be a useful marker for detecting and predicting BCa recurrence.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Shindo T, Shimizu T, Nojima M, et al. Evaluation of Urinary DNA Methylation as a Marker for Recurrent Bladder Cancer: A 2-Center Prospective Study. Urology. 2017. PMID: 29196070. doi:10.1016/j.urology.2017.11.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。